Chemotherapy News and Research

Latest Chemotherapy News and Research

Bevacizumab added to chemotherapy for NSCLC does not improve survival in elderly patients

Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.

18 Apr 2012

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, announced interim results from its ongoing MuGard Phase 4 clinical trial in oral mucositis.

18 Apr 2012

SBRT shortens radiation treatment time for gynecologic cancers

About 71,500 women in the United States are diagnosed with a gynecologic cancer every year, according to the Centers for Disease Control. Researchers from University Hospitals Case Medical Center have developed a more effective way to treat gynecologic cancers, shortening radiation treatment time from five weeks to three days. The method will be published in the Journal of Visualized Experiments (JoVE) on April 17.

18 Apr 2012

New brain cancer vaccine with material from own tumors proves effective in clinical trial

A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme-which kills thousands of Americans every year.

18 Apr 2012

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.

18 Apr 2012

Tumor microenvironment contributes critically to drug response

It should be possible to significantly improve the response of common cancers to existing "classical" chemotherapy drugs, say scientists at Cold Spring Harbor Laboratory (CSHL), by introducing agents that alter the interaction of cancer cells with their immediate surroundings, called the tumor microenvironment.

17 Apr 2012

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.

17 Apr 2012

Study: Kidney cancer growth depends on autophagy

New research at the University of Cincinnati (UC) suggests that kidney cancer growth depends on autophagy, a complex process that can provide cells with nutrients from intracellular sources. Researchers say in certain circumstances autophagy can protect tumor cells from chemotherapy, allowing them to survive for long periods of time in a hidden, dormant, metastatic state.

17 Apr 2012

Hydrophilic carbon cluster HADES can selectively kill brain cancer cells

Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.

17 Apr 2012

Two related enzymes play a key role in development of T-ALL

Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.

17 Apr 2012

Vanda acquires license from Lilly to develop and commercialize NK-1R antagonist

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, announced today that it has acquired an exclusive world-wide license from Eli Lilly and Company (Lilly) to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.

17 Apr 2012

Merck, Endocyte enter vintafolide development and commercialization agreement

Merck, known as MSD outside the United States and Canada, and Endocyte Inc., today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145).

16 Apr 2012

Immunotherapy may also help elderly cancer patients

Cancer is much more likely in the elderly than the young, and their bodies often are less prepared to fight the disease and the often-toxic side effects of treatment.

16 Apr 2012

Tool predicts response to platinum-based chemotherapy in ovarian cancer

A DNA repair pathway-focused score has the potential to help determine if first-line platinum based chemotherapy can benefit advanced-stage ovarian cancer patients, according to a study published April 13 in the Journal of the National Cancer Institute.

16 Apr 2012

Disruption of key cellular functions produces physiologic and behavioral responses

Two Massachusetts General Hospital (MGH)-based research teams, along with a group from the University of California at San Diego, have discovered that animals have a previously unknown system for detecting and responding to pathogens and toxins. In three papers published in the journals Cell and Cell Host & Microbe, the investigators describe finding evidence that disruptions to the core functions of animal cells trigger immune and detoxification responses, along with behavioral changes.

16 Apr 2012

Study identifies potential biomarkers associated with chemo resistant breast cancers

Biomarkers which could help to predict resistance to chemotherapy in breast cancer patients have been identified by researchers from the University of Hull, UK.

16 Apr 2012

Viewpoints: Politics distorting views of the health system; US is more efficient than most people think

If health insurers can keep denying coverage to anyone, millions of Americans could be left to fend for themselves in a system that openly discriminates against the sick and leaves many destitute.

16 Apr 2012

Longer looks: Diagnosing autism in minutes; Finding new uses for old drugs; Cancer war victories

Autism is an extremely complex diagnosis. Parental insight, physician observations and hours of data can factor into determining whether a child actually has the condition or is just a little on the quirky side. Now a Harvard researcher, Dennis P. Wall, has published research about a Web-based tool he developed that promises to diagnose autism in minutes, not hours -

12 Apr 2012

ALL induction treatment failure should not be an automatic indication for bone marrow transplant

International study that included St. Jude Children's Research Hospital reports some young acute lymphoblastic leukemia patients who fail induction therapy can achieve high cure rates without bone marrow transplantation.

12 Apr 2012

Scientists use two different methods to visualize rare CTCs, double positive cells in mBC

New research from The Ohio State University utilizes two different methods to visualize circulating tumor cells (CTCs) as well as other unusual circulating cells with both epithelial and hematopoietic characteristics in metastatic breast cancer.

12 Apr 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Bevacizumab added to chemotherapy for NSCLC does not improve survival in elderly patients

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

SBRT shortens radiation treatment time for gynecologic cancers

New brain cancer vaccine with material from own tumors proves effective in clinical trial

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Tumor microenvironment contributes critically to drug response

ImmunoGen commences IMGN529 Phase I trial in NHL

Study: Kidney cancer growth depends on autophagy

Hydrophilic carbon cluster HADES can selectively kill brain cancer cells

Two related enzymes play a key role in development of T-ALL

Vanda acquires license from Lilly to develop and commercialize NK-1R antagonist

Merck, Endocyte enter vintafolide development and commercialization agreement

Immunotherapy may also help elderly cancer patients

Tool predicts response to platinum-based chemotherapy in ovarian cancer

Disruption of key cellular functions produces physiologic and behavioral responses

Study identifies potential biomarkers associated with chemo resistant breast cancers

Viewpoints: Politics distorting views of the health system; US is more efficient than most people think

Longer looks: Diagnosing autism in minutes; Finding new uses for old drugs; Cancer war victories

ALL induction treatment failure should not be an automatic indication for bone marrow transplant

Scientists use two different methods to visualize rare CTCs, double positive cells in mBC

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in